Health Care & Life Sciences » Pharmaceuticals | Shire PLC

Shire PLC | Cash Flow

Fiscal year is January-December. All values GBP Millions.
2013
2014
2015
2016
2017
2018
2019
Net Income before Extraordinaries
426
2,068
853
243
3,317
186,708
109,014
Depreciation, Depletion & Amortization
208
247
417
1,087
1,758
182,127
272,446
Other Funds
1
225
45
1
21
23,448
81,450
Funds from Operations
940
2,529
1,550
2,153
3,899
345,387
300,010
Changes in Working Capital
-
39
20
182
593
34,213
2,599
Net Operating Cash Flow
939
2,568
1,530
1,971
3,305
379,600
302,609
Capital Expenditures
100
47
75
481
620
Sale of Fixed Assets & Businesses
-
-
-
1
-
Purchase/Sale of Investments
1
34
50
-
69
Net Investing Cash Flow
234
2,448
3,678
13,455
534
Cash Dividends Paid - Total
62
74
88
127
218
Issuance/Reduction of Debt, Net
13
174
410
11,759
2,675
Net Financing Cash Flow
220
337
287
11,729
2,810
Net Change in Cash
484
451
1,863
245
33
Free Cash Flow
839
2,521
1,455
1,490
2,685
Deferred Taxes & Investment Tax Credit
224
9
130
441
2,265
-
-
Net Assets from Acquisitions
146
2,493
3,635
12,952
-
Other Sources
14
77
11
8
18
Change in Capital Stock
145
11
11
96
104
Exchange Rate Effect
-
6
2
1
6
Other Uses
3
20
30
31
-

About Shire

View Profile
Address
4-1-1 Dosho-machi
Osaka Osaka 540
Japan
Employees -
Website http://www.takeda.co.jp
Updated 07/08/2019
Shire Plc is a biopharmaceutical company. It engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of medicines to meet significant unmet patient needs. The company's products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr and foznol.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.